Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study
Iván Muñoz-Repeto1,11, María José García1,11, Marta Kamieniak1, Teresa Ramón y Cajal2, Samuel Domingo1, Alicia Cazorla3, Jesús García Donas4, Susana Hernando Polo4, José Miguel García Sagredo5, Elena Hernández6, Carmen Lacambra7, Raquel Saez8, Luis Robles9, Salud Borrego10,11, Jaime Prat2, José Palacios10 and Javier Benítez1,11
1Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Center, Madrid, Spain, 2Departments of Pathology and Oncology, Hospital Sant Pau, Barcelona, Spain, 3Department of Pathology, Fundación Jiménez Díaz-CAPIO, Madrid, Spain, 4Department of Oncology, Hospital de Alcorcón, Madrid, Spain, 5Department of Genetics, Hospital Ramón y Cajal, Madrid, Spain, 6Clinical Research Programme, Spanish National Cancer Research Center, Madrid, Spain, 7Department of Internal Medicine, Hospital Severo Ochoa, Madrid, Spain, 8Laboratory of Genetics, Hospital Donostia, San Sebastián, Spain, 9Department of Oncology, Hospital Doce de Octubre, Madrid, Spain, 10Clinical Management Unit of Genetics, Reproduction and Fetal Medicine, Clinical Management Unit of Pathology and Biomedical Research Institute (IBIS), Hospital Virgen del Rocío, Sevilla, Spain and 11Biomedical Network on Rare Diseases (CIBERER), Spain.
Offprint requests to: Javier Benítez, PhD, Spanish National Cancer Center, C/ Melchor Fernández Almagro, 3. E-28029 Madrid, Spain. e-mail: firstname.lastname@example.org
Summary. The pathologic and immunohistochemical features of familial epithelial ovarian cancers are not well understood. We have carried out a comprehensive immunohistochemical study of familial ovarian carcinomas from women with and without BRCA1 or BRCA2 mutations, in order to identify specific and/or common features among these different familial case groups (BRCA1, BRCA2 and non-BRCA1/2) and to identify markers of diagnostic value that might help to select more specific treatments. 73 familial primary ovarian carcinomas were analyzed for the expression of 40 antibodies involved in different genetic pathways using a tissue microarray. Serous carcinomas comprised the majority of all three familial case groups. On the other hand, BRCA1 and BRCA2 carcinomas have similar histopathologic features; i.e. they are often high-grade and are usually diagnosed at a more advanced FIGO stage than non-BRCA1/2 carcinomas. In our series, BRCA1 carcinomas had better clinical evolution and they also more frequently over-expressed PR and P53 than BRCA2 and non-BRCA1/2carcinomas. Unsupervised cluster analysis and survival analysis identified ERCC1 as a potential marker of better clinical outcome for hereditary epithelial ovarian cancer. Histol Histopathol 28, 133-144 (2013)
Key words: Hereditary, Epithelial ovarian cancer, Immunohistochemistry